Tuesday, July 30, 2019

Aurobindo’s Sandoz deal may face further delays

Aurobindo’s Sandoz deal may face further delays In September, Hyderabad-based Aurobindo announced that it would acquire the commercial operations of Swiss drug maker Novartis AGs’ generics unit in the US for $900 million. However, the proposed deal, which could emerge as the largest outbound deal by an Indian company, is yet to see the light of day considering that the FTC is yet to respond.

from Moneycontrol Business News https://www.moneycontrol.com/news/business/aurobindo’s-sandoz-deal-may-face-further-delays_12818221.html

No comments:

Post a Comment

Vikas Khemani on key triggers that will shape the market’s next big move

Most people kind of turned bearish on global concerns, oil prices. So, people tend to kind of extrapolate more bad news. So that has happene...